No insider purchase over the last 90 days. The latest, by Fox James, was filed 10 Mar 2020.
GenMark Diagnostics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for GenMark Diagnostics, Inc. The previous disclosure was published on 29 December 2020.
Our records for GenMark Diagnostics, Inc. go back to 2016, with 3 purchases and 150 sales on the open market in total.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
25 of 199 declarations
GenMark Diagnostics, Inc. is a company focused on the development of molecular diagnostic tests. It specializes in providing solutions for the rapid diagnosis of infections and diseases.
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2020 | 171.6 m USD | -18.6 m USD | n.d. | 10-K |
| Dec 2019 | 88.0 m USD | -47.4 m USD | n.d. | 10-K |
| Dec 2018 | 70.8 m USD | -50.5 m USD | n.d. | 10-K |
| Dec 2017 | 52.5 m USD | -61.9 m USD | n.d. | 10-K |
| Dec 2016 | 49.3 m USD | -50.6 m USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.